{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:54:22Z","timestamp":1791021262150,"version":"4.1.0"},"reference-count":113,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: Peritoneal metastases (PMs) remain difficult to treat because the peritoneum\u2013plasma barrier limits drug penetration from the systemic circulation. Intraperitoneal chemotherapy (IPC), particularly repeated intraperitoneal (IP) administration via implantable ports, can achieve high local drug exposure with prolonged retention. This review summarizes the pharmacological rationale, clinical evidence, and future directions of catheter-based IPC, with emphasis on combined IP and systemic chemotherapy for ovarian, gastric, and pancreatic cancers. Methods: We narratively reviewed prospective clinical trials and key retrospective studies evaluating IPC and compared repeated catheter-based IPC with hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC). Efficacy, safety, practice considerations, and opportunities for ascites-based monitoring were examined. Results: In ovarian cancer, several randomized trials demonstrated improved progression-free survival (PFS), and in selected trials, improved overall survival (OS) was demonstrated using IP plus intravenous (IV) therapy, although in the latter trials, toxicity and catheter-related complications limited treatment completion. A phase III Intraperitoneal Therapy for Ovarian Cancer with Carboplatin (iPocc) trial further showed significantly prolonged PFS with IP carboplatin and weekly paclitaxel, with non-catheter-related toxicity comparable to that of IV therapy. In gastric and pancreatic cancer, phase II studies reported symptomatic control, cytologic conversion, and higher rates of conversion surgery in selected patients, although confirmatory phase III data are limited. Device complications, including infection, obstruction, and leakage, occurred, but were manageable. Conclusions: Repeated catheter-based IPC is a feasible approach that enhances intraperitoneal drug delivery and complements IV chemotherapy. Future priorities include randomized trials, pharmacokinetic optimization, and biomarker-guided patient selection, supported by serial ascites assessment to refine indications and improve outcomes.<\/jats:p>","DOI":"10.3390\/pharmaceutics18020179","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:09:22Z","timestamp":1769771362000},"page":"179","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combined Intraperitoneal and Systemic Chemotherapy for Peritoneal Metastases: Drug Delivery Concepts, Pharmacokinetics, and Clinical Applications: A Narrative Review"],"prefix":"10.3390","volume":"18","author":[{"given":"Kohei","family":"Tamura","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5708-7130","authenticated-orcid":false,"given":"Joji","family":"Kitayama","sequence":"additional","affiliation":[{"name":"Department of Surgery, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan"},{"name":"Department of Translational Research, Clinical Research Center, Jichi Medical University Hospital, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Saga","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1744-5570","authenticated-orcid":false,"given":"Yuji","family":"Takei","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8888-9937","authenticated-orcid":false,"given":"Hiroyuki","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8371-9410","authenticated-orcid":false,"given":"Hironori","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryozo","family":"Nagai","sequence":"additional","affiliation":[{"name":"Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Aizawa","sequence":"additional","affiliation":[{"name":"Department of Translational Research, Clinical Research Center, Jichi Medical University Hospital, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan"},{"name":"Clinical Pharmacology Center, Jichi Medical University Hospital, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"EVIDoa2200225","DOI":"10.1056\/EVIDoa2200225","article-title":"Intraperitoneal Carboplatin for Ovarian Cancer\u2014A Phase 2\/3 Trial","volume":"2","author":"Nagao","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/bjs.11792","article-title":"Phase I\/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis","volume":"107","author":"Yamada","year":"2020","journal-title":"Br. J. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1200\/JCO.22.02867","article-title":"Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer with Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial","volume":"42","author":"Rau","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sommariva, A., Tonello, M., Coccolini, F., De Manzoni, G., Delrio, P., Pizzolato, E., Gelmini, R., Serra, F., Rreka, E., and Pasqual, E.M. (2022). Colorectal Cancer with Peritoneal Metastases: The Impact of the Results of PROPHYLOCHIP, COLOPEC, and PRODIGE 7 Trials on Peritoneal Disease Management. Cancers, 15.","DOI":"10.3390\/cancers15010165"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.22.02644","article-title":"Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients with Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial","volume":"42","author":"Zwanenburg","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.24.00686","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18)","volume":"43","author":"Fagotti","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jconrel.2024.07.017","article-title":"Intraperitoneal drug delivery systems for peritoneal carcinomatosis: Bridging the gap between research and clinical implementation","volume":"373","author":"Ramis","year":"2024","journal-title":"J. Control Release"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40265-025-02195-9","article-title":"A Clinical Pharmacological Perspective on Intraperitoneal Chemotherapy","volume":"85","author":"Rietveld","year":"2025","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Saito, A., Kitayama, J., Nagai, R., and Aizawa, K. (2023). Anatomical Targeting of Anticancer Drugs to Solid Tumors Using Specific Administration Routes: Review. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15061664"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-022-01828-7","article-title":"Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies","volume":"83","author":"Guchelaar","year":"2023","journal-title":"Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.21037\/tgh.2016.08.03","article-title":"Intraperitoneal free cancer cells in gastric cancer: Pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy\/hyperthermic intraperitoneal chemotherapy in gastric cancer","volume":"1","author":"Ji","year":"2016","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_15","first-page":"45","article-title":"Chemotherapy for intraperitoneal use: A review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy","volume":"7","author":"Goodman","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1515\/pp-2017-0010","article-title":"Pharmacological principles of intraperitoneal and bidirectional chemotherapy","volume":"2","author":"Michelakis","year":"2017","journal-title":"Pleura Peritoneum"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.21037\/jgo-2020-03","article-title":"Intraperitoneal paclitaxel: Pharmacology, clinical results and future prospects","volume":"12","author":"Sugarbaker","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jss.2008.06.049","article-title":"Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration","volume":"155","author":"Soma","year":"2009","journal-title":"J. Surg. Res."},{"key":"ref_19","first-page":"29","article-title":"Surgical technology and pharmacology of hyperthermic perioperative chemotherapy","volume":"7","author":"Sugarbaker","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_20","first-page":"38","article-title":"In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration","volume":"12","author":"Alberts","year":"1985","journal-title":"Semin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lim, P.Q., Han, I.H., Seow, K.M., and Chen, K.H. (2022). Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231710078"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10120-019-00978-0","article-title":"Peritoneal metastasis in gastric cancer: Results from the German database","volume":"23","author":"Rau","year":"2020","journal-title":"Gastric Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.18.01688","article-title":"Cytoreductive Surgery with or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis","volume":"37","author":"Bonnot","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/02656736.2017.1283066","article-title":"Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer","volume":"33","author":"Cowan","year":"2017","journal-title":"Int. J. Hyperth."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1002\/cncr.25116","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis","volume":"116","author":"Franko","year":"2010","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/bjc.2014.419","article-title":"Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone","volume":"111","author":"Mirnezami","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ejso.2016.03.017","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours","volume":"42","author":"Ansari","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"103841","DOI":"10.1016\/j.critrevonc.2022.103841","article-title":"Characteristics of gastric cancer around the world","volume":"181","author":"Carbajal","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/bjs.4695","article-title":"Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion","volume":"92","author":"Yonemura","year":"2005","journal-title":"Br. J. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000658-198807000-00005","article-title":"Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding","volume":"208","author":"Fujimoto","year":"1988","journal-title":"Ann. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","article-title":"Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: First evidence for efficacy","volume":"21","author":"Solass","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: Rationale, evidence, and potential indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1758835920940887","DOI":"10.1177\/1758835920940887","article-title":"Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma","volume":"12","author":"Sgarbura","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-20-2152","article-title":"PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Robella, M., De Simone, M., Berchialla, P., Argenziano, M., Borsano, A., Ansari, S., Abollino, O., Ficiar\u00e0, E., Cinquegrana, A., and Cavalli, R. (2021). A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis. Cancers, 13.","DOI":"10.3390\/cancers13051060"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"104151","DOI":"10.1016\/j.ebiom.2022.104151","article-title":"Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases","volume":"82","author":"Ceelen","year":"2022","journal-title":"EBioMedicine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejso.2020.05.021","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer","volume":"47","author":"Alyami","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Khosrawipour, T., Khosrawipour, V., and Giger-Pabst, U. (2017). Pressurized Intra Peritoneal Aerosol Chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186709"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2743985","DOI":"10.1155\/2018\/2743985","article-title":"Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study","volume":"2018","author":"Kurtz","year":"2018","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.ejso.2017.09.010","article-title":"Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis","volume":"43","author":"Alyami","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"20180113","DOI":"10.1515\/pp-2018-0113","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo na\u00efve upper gi-adenocarcinomas with peritoneal seeding\u2014A phase II\/III trial of the AIO\/CAOGI\/ACO","volume":"3","author":"Pabst","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"20180114","DOI":"10.1515\/pp-2018-0114","article-title":"PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer","volume":"3","author":"Bakrin","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1245\/s10434-020-08583-7","article-title":"What Drives High Costs of Cytoreductive Surgery and HIPEC: Patient, Provider or Tumor?","volume":"27","author":"Schwartz","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1002\/cam4.5277","article-title":"Study of SOX combined with intraperitoneal high-dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: A phase II single-arm clinical trial","volume":"12","author":"Tu","year":"2023","journal-title":"Cancer Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13063-022-06143-w","article-title":"SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: A prospective observation","volume":"23","author":"Bin","year":"2022","journal-title":"Trials"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1245\/s10434-022-11998-z","article-title":"Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases","volume":"29","author":"Chia","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1245\/s10434-020-09388-4","article-title":"Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Oxaliplatin as Induction Therapy for Patients with Advanced Gastric Cancer with Peritoneal Metastases","volume":"28","author":"Saito","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0090-8258(85)90118-0","article-title":"Clinical pharmacology of intraperitoneal cisplatin","volume":"20","author":"Lopez","year":"1985","journal-title":"Gynecol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/cyto.b.21978","article-title":"Flow cytometry-based analysis of tumor-leukocyte ratios in peritoneal fluid from patients with advanced gastric cancer","volume":"100","author":"Takahashi","year":"2021","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Takahashi, K., Kurashina, K., Yamaguchi, H., Kanamaru, R., Ohzawa, H., Miyato, H., Saito, S., Hosoya, Y., Lefor, A.K., and Sata, N. (2022). Altered intraperitoneal immune microenvironment in patients with peritoneal metastases from gastric cancer. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.969468"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-024-04727-8","article-title":"Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy","volume":"95","author":"Zhang","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"300060520986664","DOI":"10.1177\/0300060520986664","article-title":"Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites","volume":"49","author":"Kou","year":"2021","journal-title":"J. Int. Med. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5694\/mja2.52227","article-title":"Screening and prevention of ovarian cancer","volume":"220","author":"Sideris","year":"2024","journal-title":"Med. J. Aust."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1102\/1470-7330.2012.9002","article-title":"Recent advances in systemic treatments for ovarian cancer","volume":"12","author":"Banerjee","year":"2012","journal-title":"Cancer Imaging"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","article-title":"Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_60","first-page":"1686","article-title":"Pancreatic cancer: An increasing global public health concern","volume":"71","author":"Cabasag","year":"2022","journal-title":"Gut"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"10740","DOI":"10.3748\/wjg.v20.i31.10740","article-title":"Borderline resectable pancreatic cancer: Definitions and management","volume":"20","author":"Lopez","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1072-7515(99)00075-7","article-title":"Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985\u20131995, using the National Cancer Database","volume":"189","author":"Sener","year":"1999","journal-title":"J. Am. Coll. Surg."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MPA.0b013e31825abf8c","article-title":"Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: A population-based study","volume":"42","author":"Thomassen","year":"2013","journal-title":"Pancreas"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2018.10.008","article-title":"Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis","volume":"106","author":"Mackay","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MPA.0000000000000290","article-title":"Pancreatic cancer with malignant ascites: Clinical features and outcomes","volume":"44","author":"Takahara","year":"2015","journal-title":"Pancreas"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.gassur.2006.07.013","article-title":"The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma","volume":"10","author":"Ferrone","year":"2006","journal-title":"J. Gastrointest. Surg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/SLA.0000000000001705","article-title":"Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel with S-1 for Pancreatic Ductal Adenocarcinoma Patients with Peritoneal Metastasis","volume":"265","author":"Satoi","year":"2017","journal-title":"Ann. Surg."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13063-022-06049-7","article-title":"Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)","volume":"23","author":"Yamamoto","year":"2023","journal-title":"Trials"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Rijken, A., Lurvink, R.J., Luyer, M.D.P., Nieuwenhuijzen, G.A.P., van Erning, F.N., van Sandick, J.W., and de Hingh, I.H.J.T. (2021). The Burden of Peritoneal Metastases from Gastric Cancer: A Systematic Review on the Incidence, Risk Factors and Survival. J. Clin. Med., 10.","DOI":"10.3390\/jcm10214882"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s10120-021-01160-1","article-title":"Synchronous peritoneal metastases of gastric cancer origin: Incidence, treatment and survival of a nationwide Dutch cohort","volume":"24","author":"Koemans","year":"2021","journal-title":"Gastric Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"78120","DOI":"10.18632\/oncotarget.17696","article-title":"Peritoneal recurrence in gastric cancer following curative resection can be predicted by postoperative but not preoperative biomarkers: A single-institution study of 320 cases","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","article-title":"The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer","volume":"79","author":"Desiderio","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1016\/j.ejso.2021.05.016","article-title":"Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: A meta-analysis of randomized controlled trials","volume":"47","author":"Granieri","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1245\/s10434-021-11316-z","article-title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: A 12-Year Meta-Analysis of this Promising Treatment Strategy for Advanced Gastric Cancer at Different Stages","volume":"29","author":"Zhang","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/annonc\/mdp260","article-title":"Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis","volume":"21","author":"Ishigami","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.28204","article-title":"A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis","volume":"119","author":"Yamaguchi","year":"2013","journal-title":"Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1245\/s10434-023-14240-6","article-title":"Phase II Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 and Cisplatin for Gastric Cancer with Peritoneal Metastasis","volume":"31","author":"Kobayashi","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"109603","DOI":"10.1016\/j.ejso.2025.109603","article-title":"Intraperitoneal paclitaxel with systemic S-1 plus oxaliplatin for advanced or recurrent gastric cancer with peritoneal metastasis: A single-arm, multicenter phase II clinical trial","volume":"51","author":"Seo","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Senthil, M., and Dayyani, F. (2023). Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis\u2014STOPGAP trial. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10680-1"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/fon-2021-1414","article-title":"A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis","volume":"18","author":"Lu","year":"2022","journal-title":"Future Oncol."},{"key":"ref_85","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","author":"Segelman","year":"2012","journal-title":"Br. J. Surg."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/bjc.2013.82","article-title":"Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: A longitudinal experience of 2406 patients over two decades","volume":"108","author":"Kerscher","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_88","first-page":"e41","article-title":"Bevacizumab in Addition to Palliative Chemotherapy for Patients with Peritoneal Carcinomatosis of Colorectal Origin: A Nationwide Population-Based Study","volume":"15","author":"Razenberg","year":"2016","journal-title":"Clin. Color. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1245\/s10434-006-9167-9","article-title":"Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis","volume":"14","author":"Elias","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ejso.2012.03.001","article-title":"Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: Prognosis and treatment of recurrences in a cohort study","volume":"38","author":"Cashin","year":"2012","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1245\/s10434-013-3145-9","article-title":"Cytoreduction and HIPEC in the Netherlands: Nationwide long-term outcome following the Dutch protocol","volume":"20","author":"Kuijpers","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Elias","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_95","first-page":"6852749","article-title":"Feasibility and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Carcinomatosis: A Retrospective Cohort Study","volume":"2017","author":"Grass","year":"2017","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Sleiman, M.J., Jelip, A., Buchs, N., Toso, C., Liot, E., Koessler, T., Meyer, J., Meurette, G., and Ris, F. (2024). Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Carcinomatosis in Colorectal Cancer Patients: A Systematic Review of the Evidence. Cancers, 16.","DOI":"10.3390\/cancers16213661"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.21037\/jgo-20-257","article-title":"Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases-a systematic review","volume":"12","author":"Lurvink","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00384-023-04434-5","article-title":"Intraperitoneal paclitaxel combined with FOLFOX\/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): Study protocol of a single arm, multicenter, phase 2 study","volume":"38","author":"Murono","year":"2023","journal-title":"Int. J. Color. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e206363","DOI":"10.1001\/jamasurg.2020.6363","article-title":"The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery","volume":"156","author":"Kusamura","year":"2021","journal-title":"JAMA Surg."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10434-999-0727-7","article-title":"Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy","volume":"6","author":"Sugarbaker","year":"1999","journal-title":"Ann. Surg. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1245\/s10434-016-5529-0","article-title":"Early Postoperative Intraperitoneal Chemotherapy for Low-Grade Appendiceal Mucinous Neoplasms with Pseudomyxoma Peritonei: Is it Beneficial?","volume":"24","author":"Huang","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Prabhu, A., Brandl, A., Wakama, S., Sako, S., Ishibashi, H., Mizumoto, A., Takao, N., Noguchi, K., Motoi, S., and Ichinose, M. (2020). Neoadjuvant Intraperitoneal Chemotherapy in Patients with Pseudomyxoma Peritonei-A Novel Treatment Approach. Cancers, 12.","DOI":"10.3390\/cancers12082212"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/j.ejso.2018.05.021","article-title":"Is there an oncological interest in the combination of CRS\/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study","volume":"44","author":"Mehta","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12957-024-03426-1","article-title":"Long-term survival outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of hepatocellular carcinoma patients","volume":"22","author":"Yan","year":"2024","journal-title":"World J. Surg. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2147\/CMAR.S555348","article-title":"The Prophylactic Role of Hyperthermic Intraperitoneal Chemotherapy on Spontaneously Ruptured Hepatocellular Carcinoma with Radical Resection: A Retrospective Study","volume":"17","author":"Li","year":"2025","journal-title":"Cancer Manag. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"121534","DOI":"10.1016\/j.biomaterials.2022.121534","article-title":"Ultra-high drug loading improves nanoparticle efficacy against peritoneal mesothelioma","volume":"285","author":"Sabatelle","year":"2022","journal-title":"Biomaterials"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Tamura, K., Kimura, N., Ohzawa, H., Miyato, H., Sata, N., Koyanagi, T., Saga, Y., Takei, Y., Fujiwara, H., and Nagai, R. (2024). Optimizing Timing of Intraperitoneal Chemotherapy to Enhance Intravenous Carboplatin Concentration. Cancers, 16.","DOI":"10.3390\/cancers16162841"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Christou, N., Auger, C., Battu, S., Lallou\u00e9, F., Jauberteau-Marchan, M.O., Hervieu, C., Verdier, M., and Mathonnet, M. (2021). Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives. Biology, 10.","DOI":"10.3390\/biology10030225"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41416-024-02717-4","article-title":"Metastasis-associated fibroblasts in peritoneal surface malignancies","volume":"131","author":"Ramos","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"11913","DOI":"10.1038\/s41598-020-68639-2","article-title":"Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer","volume":"10","author":"Asem","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"9545","DOI":"10.3390\/ijms13089545","article-title":"Implication of tumor microenvironment in chemoresistance: Tumor-associated stromal cells protect tumor cells from cell death","volume":"13","author":"Castells","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/02656736.2021.1945688","article-title":"Hyperthermic intraperitoneal chemotherapy enhances antitumor effects on ovarian cancer through immune-mediated cancer stem cell targeting","volume":"38","author":"Wu","year":"2021","journal-title":"Int. J. Hyperth."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.trecan.2019.12.008","article-title":"Targeting the Tumor Microenvironment in Colorectal Peritoneal Metastases","volume":"6","author":"Ceelen","year":"2020","journal-title":"Trends Cancer"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/2\/179\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:14:11Z","timestamp":1769771651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/2\/179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":113,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["pharmaceutics18020179"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18020179","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}